Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by loco-regional radiotherapy.
Large B-cell Diffuse Lymphoma of Testis
DRUG: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
Adverse Events Assessment, Number of patients who withdrew the treatment due to adverse event, From treatment start until the last drug administration, up to week 22 for the 'R-CHOP, Depocyte, Methotrexate' Group, up to 15 weeks (Weeks 1-15) for the 'R-CHOP + Lyposomal Cytarabine' Group, and from week 18-22 for the 'HD-MTX' Group
5 Year Cumulative Incidence of Progressions, Percentage of patients with disease progression after achieving a remission, From the first documented response to relapse until 5 years from study entry|5 Years Progression Free Survival (PFS), Percentage of patients free from disease progression after 5 years from study entry, From study entry until 5 years after|5 Years Overall Survival (OS), Percentage of patients alive after 5 years from study entry, From study entry until 5 years after
This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by loco-regional radiotherapy.